Your browser doesn't support javascript.
loading
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara, Mikiya; Kitano, Shigehisa; Kageyama, Shinichi; Miyahara, Yoshihiro; Yamamoto, Noboru; Kato, Hidefumi; Mishima, Hideyuki; Hattori, Hiroyoshi; Funakoshi, Takeru; Kojima, Takashi; Sasada, Tetsuro; Sato, Eiichi; Okamoto, Sachiko; Tomura, Daisuke; Nukaya, Ikuei; Chono, Hideto; Mineno, Junichi; Kairi, Muhammad Faris; Diem Hoang Nguyen, Phuong; Simoni, Yannick; Nardin, Alessandra; Newell, Evan; Fehlings, Michael; Ikeda, Hiroaki; Watanabe, Takashi; Shiku, Hiroshi.
Afiliação
  • Ishihara M; Cancer Center, Mie University Hospital, Tsu, Japan.
  • Kitano S; Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kageyama S; Department of Experimental Therapeutics, National Cancer Institue Hospital, Tokyo, Japan.
  • Miyahara Y; Departments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan kageyama@med.mie-u.ac.jp.
  • Yamamoto N; Departments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
  • Kato H; Department of Experimental Therapeutics, National Cancer Institue Hospital, Tokyo, Japan.
  • Mishima H; Department of Transfusion Medicine, Aichi Medical University, Nagakute, Japan.
  • Hattori H; Cancer Center, Aichi Medical University, Nagakute, Japan.
  • Funakoshi T; Laboratory of Advanced Therapy, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Kojima T; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
  • Sasada T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Sato E; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
  • Okamoto S; Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
  • Tomura D; Takara Bio Inc, Kusatsu, Japan.
  • Nukaya I; Takara Bio Inc, Kusatsu, Japan.
  • Chono H; Takara Bio Inc, Kusatsu, Japan.
  • Mineno J; Takara Bio Inc, Kusatsu, Japan.
  • Kairi MF; Takara Bio Inc, Kusatsu, Japan.
  • Diem Hoang Nguyen P; ImmunoScape Pte. Ltd, Singapore.
  • Simoni Y; ImmunoScape Pte. Ltd, Singapore.
  • Nardin A; ImmunoScape Pte. Ltd, Singapore.
  • Newell E; ImmunoScape Pte. Ltd, Singapore.
  • Fehlings M; ImmunoScape Pte. Ltd, Singapore.
  • Ikeda H; ImmunoScape Pte. Ltd, Singapore.
  • Watanabe T; Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Shiku H; Departments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
J Immunother Cancer ; 10(6)2022 06.
Article em En | MEDLINE | ID: mdl-35768164
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Síndrome da Liberação de Citocina / Imunoterapia / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Síndrome da Liberação de Citocina / Imunoterapia / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article